{"id":"W3012293314","doi":"10.2217/fon-2020-0044","title":"MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Cytarabine; Myeloid leukemia; Refractory (planetary science); Internal medicine; Placebo; Oncology; Randomized controlled trial; Myeloid; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002664284,0.0005248872,0.004723516,0.0005064848,0.00007537776,0.00001448527,0.0004852675,0.001046344,0.001776293],"category_scores_gemma":[0.003186089,0.00035911,0.000623839,0.0008956362,0.00051723,0.0001133897,0.0001937828,0.002086558,0.0001463242],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001983862,"about_ca_system_score_gemma":0.005715582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001969036,"about_ca_topic_score_gemma":0.00016548,"domain_scores_codex":[0.994016,0.001581616,0.002015001,0.0008308835,0.0007222727,0.0008342284],"domain_scores_gemma":[0.9953237,0.002426984,0.0007347366,0.0006363766,0.0002860965,0.000592076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9368089,0.001131992,0.000006092655,0.0001404567,0.0009252265,0.002551056,0.001983457,0.0000110721,0.0225974,0.0001452237,0.02459714,0.009102022],"study_design_scores_gemma":[0.8974115,0.01363606,0.000007499333,0.00007082944,0.0007894085,0.0001634441,0.0007497107,0.003182622,0.001067593,0.00003189383,0.08261053,0.0002788886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9449093,0.001093969,0.0002253899,0.03115807,0.001142593,0.01253603,0.00007783485,0.0001794992,0.008677267],"genre_scores_gemma":[0.9629622,0.003614001,0.006628453,0.009326775,0.007870532,0.002677107,0.0004176801,0.000218166,0.006285098],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05801339,"threshold_uncertainty_score":0.9999211,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02589568544120383,"score_gpt":0.3477053238999175,"score_spread":0.3218096384587137,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}